SnoN suppresses TGF-β-induced epithelial-mesenchymal transition and invasion of bladder cancer in a TIF1γ-dependent manner

Yin,Xinbao; Xu,Chuanshen; Zheng,Xueping; Yuan,Huiyang; Liu,Ming; Qiu,Yue; Chen,Jun

doi:10.3892/or.2016.4939

SnoN suppresses TGF-β-induced epithelial-mesenchymal transition and invasion of bladder cancer in a TIF1γ-dependent manner

Authors:
- Xinbao Yin
- Chuanshen Xu
- Xueping Zheng
- Huiyang Yuan
- Ming Liu
- Yue Qiu
- Jun Chen
View Affiliations

Affiliations: Department of Urology, Qilu Hospital of Shandong University, Qingdao, Shandong 266035, P.R. China, Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China
Published online on: July 15, 2016 https://doi.org/10.3892/or.2016.4939
Pages: 1535-1541

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The transcriptional regulator SnoN (also known as SKI-like proto-oncogene, SKIL), a member of the Ski family, has been reported to influence epithelial-mesenchymal transition (EMT) in response to TGF-β. In the present study, we investigated the role of SnoN in bladder cancer (BC). Differential expression of SnoN was not detected in BC tissues compared with that noted in adjacent non-cancerous tissues. SnoN was upregulated in response to TGF-β treatment, but had no effect on the TGF-β pathway, which may be explained by the low level of SnoN SUMOylation. TIF1γ, which catalyzes the SUMOylation of SnoN, was downregulated in BC tissues. Overexpression of TIF1γ restored the ability of SnoN to suppress the TGF-β pathway. Furthermore, TGF-β-induced EMT and invasion of BC cells were suppressed by TIF1γ in the presence of SnoN. Collectirely, our data suggest that SnoN suppresses TGF-β‑induced EMT and invasion of BC cells in a TIF1γ‑dependent manner and may serve as a novel therapeutic option for the treatment of BC.

View Figures

View References

1	Griffiths TR; Action on Bladder Cancer: Current perspectives in bladder cancer management. Int J Clin Pract. 67:435–448. 2013. View Article : Google Scholar
2	Kaufman DS, Shipley WU and Feldman AS: Bladder cancer. Lancet. 374:239–249. 2009. View Article : Google Scholar : PubMed/NCBI
3	Parekh DJ, Bochner BH and Dalbagni G: Superficial and muscle-invasive bladder cancer: Principles of management for outcomes assessments. J Clin Oncol. 24:5519–5527. 2006. View Article : Google Scholar : PubMed/NCBI
4	Gold LI: The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit Rev Oncog. 10:303–360. 1999.
5	Fabregat I, Fernando J, Mainez J and Sancho P: TGF-beta signaling in cancer treatment. Curr Pharm Des. 20:2934–2947. 2014. View Article : Google Scholar
6	Katsuno Y, Lamouille S and Derynck R: TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol. 25:76–84. 2013. View Article : Google Scholar
7	Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F and Liu Y: TGF-β-induced upregulation of malat1 promotes bladder cancer metastasis by associating with suz12. Clin Cancer Res. 20:1531–1541. 2014. View Article : Google Scholar : PubMed/NCBI
8	Geng J, Fan J, Ouyang Q, Zhang X, Zhang X, Yu J, Xu Z, Li Q, Yao X, Liu X, et al: Loss of PPM1A expression enhances invasion and the epithelial-to-mesenchymal transition in bladder cancer by activating the TGF-β/Smad signaling pathway. Oncotarget. 5:5700–5711. 2014. View Article : Google Scholar : PubMed/NCBI
9	Saitoh M: Epithelial-mesenchymal transition is regulated at post-transcriptional levels by transforming growth factor-β signaling during tumor progression. Cancer Sci. 106:481–488. 2015. View Article : Google Scholar : PubMed/NCBI
10	Miyazono K: Positive and negative regulation of TGF-beta signaling. J Cell Sci. 113:1101–1109. 2000.PubMed/NCBI
11	Zeglinski MR, Hnatowich M, Jassal DS and Dixon IM: SnoN as a novel negative regulator of TGF-β/Smad signaling: A target for tailoring organ fibrosis. Am J Physiol Heart Circ Physiol. 308:H75–H82. 2015. View Article : Google Scholar
12	Krakowski AR, Laboureau J, Mauviel A, Bissell MJ and Luo K: Cytoplasmic SnoN in normal tissues and nonmalignant cells antagonizes TGF-beta signaling by sequestration of the Smad proteins. Proc Natl Acad Sci USA. 102:12437–12442. 2005. View Article : Google Scholar : PubMed/NCBI
13	Tecalco-Cruz AC, Sosa-Garrocho M, Vázquez-Victorio G, Ortiz-García L, Domínguez-Hüttinger E and Macías-Silva M: Transforming growth factor-β/SMAD Target gene SKIL is negatively regulated by the transcriptional cofactor complex SNON-SMAD4. J Biol Chem. 287:26764–26776. 2012. View Article : Google Scholar : PubMed/NCBI
14	Stroschein SL, Wang W, Zhou S, Zhou Q and Luo K: Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. Science. 286:771–774. 1999. View Article : Google Scholar : PubMed/NCBI
15	Ikeuchi Y, Dadakhujaev S, Chandhoke AS, Huynh MA, Oldenborg A, Ikeuchi M, Deng L, Bennett EJ, Harper JW, Bonni A, et al: TIF1γ protein regulates epithelial-mesenchymal transition by operating as a small ubiquitin-like modifier (SUMO) E3 ligase for the transcriptional regulator SnoN1. J Biol Chem. 289:25067–25078. 2014. View Article : Google Scholar : PubMed/NCBI
16	Hsu YH, Sarker KP, Pot I, Chan A, Netherton SJ and Bonni S: Sumoylated SnoN represses transcription in a promoter-specific manner. J Biol Chem. 281:33008–33018. 2006. View Article : Google Scholar : PubMed/NCBI
17	Johnson ES: Protein modification by SUMO. Annu Rev Biochem. 73:355–382. 2004. View Article : Google Scholar : PubMed/NCBI
18	Pot I and Bonni S: SnoN in TGF-beta signaling and cancer biology. Curr Mol Med. 8:319–328. 2008. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar
20	Holz JD, Beier E, Sheu TJ, Ubayawardena R, Wang M, Sampson ER, Rosier RN, Zuscik M and Puzas JE: Lead induces an osteoarthritis-like phenotype in articular chondrocytes through disruption of TGF-β signaling. J Orthop Res. 30:1760–1766. 2012. View Article : Google Scholar : PubMed/NCBI
21	Netherton SJ and Bonni S: Suppression of TGFβ-induced epithelial-mesenchymal transition like phenotype by a PIAS1 regulated sumoylation pathway in NMuMG epithelial cells. PLoS One. 5:e139712010. View Article : Google Scholar
22	Peng H, Feldman I and Rauscher FJ III: Hetero-oligomerization among the TIF family of RBCC/TRIM domain-containing nuclear cofactors: A potential mechanism for regulating the switch between coactivation and corepression. J Mol Biol. 320:629–644. 2002. View Article : Google Scholar : PubMed/NCBI
23	Li Y, Yang K, Mao Q, Zheng X, Kong D and Xie L: Inhibition of TGF-beta receptor I by siRNA suppresses the motility and invasiveness of T24 bladder cancer cells via modulation of integrins and matrix metalloproteinase. Int Urol Nephrol. 42:315–323. 2010. View Article : Google Scholar
24	Zhao B and Chen YG: Regulation of TGF-β signal transduction. Scientifica (Cairo). 2014:8740652014.
25	Imoto I, Pimkhaokham A, Fukuda Y, Yang ZQ, Shimada Y, Nomura N, Hirai H, Imamura M and Inazawa J: SNO is a probable target for gene amplification at 3q26 in squamous-cell carcinomas of the esophagus. Biochem Biophys Res Commun. 286:559–565. 2001. View Article : Google Scholar : PubMed/NCBI
26	Zhang F, Lundin M, Ristimäki A, Heikkilä P, Lundin J, Isola J, Joensuu H and Laiho M: Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Res. 63:5005–5010. 2003.PubMed/NCBI
27	Jahchan NS, Ouyang G and Luo K: Expression profiles of SnoN in normal and cancerous human tissues support its tumor suppressor role in human cancer. PLoS One. 8:e557942013. View Article : Google Scholar : PubMed/NCBI
28	Hatakeyama S: TRIM proteins and cancer. Nat Rev Cancer. 11:792–804. 2011. View Article : Google Scholar : PubMed/NCBI
29	He W, Dorn DC, Erdjument-Bromage H, Tempst P, Moore MA and Massagué J: Hematopoiesis controlled by distinct TIF1γ and Smad4 branches of the TGFβ pathway. Cell. 125:929–941. 2006. View Article : Google Scholar : PubMed/NCBI
30	Dupont S, Mamidi A, Cordenonsi M, Montagner M, Zacchigna L, Adorno M, Martello G, Stinchfield MJ, Soligo S, Morsut L, et al: FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell. 136:123–135. 2009. View Article : Google Scholar : PubMed/NCBI
31	Jain S, Singhal S, Francis F, Hajdu C, Wang JH, Suriawinata A, Wang YQ, Zhang M, Weinshel EH, Francois F, et al: Association of overexpression of TIF1γ with colorectal carcinogenesis and advanced colorectal adenocarcinoma. World J Gastroenterol. 17:3994–4000. 2011. View Article : Google Scholar : PubMed/NCBI
32	Ding ZY, Jin GN, Wang W, Chen WX, Wu YH, Ai X, Chen L, Zhang WG, Liang HF, Laurence A, et al: Reduced expression of transcriptional intermediary factor 1 gamma promotes metastasis and indicates poor prognosis of hepatocellular carcinoma. Hepatology. 60:1620–1636. 2014. View Article : Google Scholar : PubMed/NCBI